EUVIMEDEUVIMED entdecken
Crossref

Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience

Rima Patel, Cao Jin, Diana Jaber, Nicole Casasanta, Mayuri Jain, Weijia Fu, Catherine Wu, Erin Moshier, Amy Tiersten

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2024.12.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Rima Patel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Rima.…. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: There is limited data on the use of low dose tamoxifen (LDT) for chemoprevention since its introduction in 2019. This study sought to determine the rate of LDT uptake at our institution and describe factors associated with its use. METHODS: We performed a retrospective chart review of women diagnosed with ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and/or atypical hyperplasia from 2019 to 2021. Log-binomial models were used to compare the probabilities of receiving standard dose tamoxifen (SDT) relative to LDT by patient and disease characteristics. Since most patients did not experience any AEs, a zero-inflated poison regression model was used to estimate and compare adverse event rates between groups. RESULTS: Among 477 patients with DCIS, LCIS, and atypical hyperplasia, 27% (N = 129) initiated SDT, 19% (N = 89) LDT, 32% (N = 155) aromatase inhibitor, 2% (N = 9) raloxifene, and 20% (N = 95) declined therapy. LDT was used more frequently than SDT in patients with LCIS or atypical hyperplasia compared to DCIS (31.4% vs 17.4%, P < .0001). There were no significant differences in the frequency of adverse events between patients on SDT and LDT but the incidence rate of AEs in the SDT group was higher (1.9 vs. 1.3 per 1000 days, P = .0186). CONCLUSION: In our population, 19% of women with DCIS, LCIS, or atypical hyperplasia, initiated chemoprevention with LDT with higher usage in patients with atypical lesions and/or LCIS. Physicians should strongly consider LDT in women with high-risk lesions who are eligible for chemoprevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingAntineoplastic Agents, HormonalCarcinoma, LobularHumansFemaleRetrospective StudiesMiddle AgedAgedAdult

Stichwörter der Autor:innen

Atypical hyperplasiaChemopreventionDuctal carcinoma in situ (DCIS)Lobular carcinoma in situ (LCIS)Tamoxifen

Substanzen

TamoxifenAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Rima.patel2@mssm.edu.
  • Department of Pathology, Northwell Health, New York, NY.
  • Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Department of Medicine, Division of Hematology and Medical Oncology, Yale School of Medicine, New Haven, CT.
  • Division of Biostatistics, Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Zitieren

APA

Patel, R., Jin, C., Jaber, D., Casasanta, N., Jain, M., Fu, W., Wu, C., Moshier, E., & Tiersten, A. (2025). Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.12.020

Vancouver

Patel R, Jin C, Jaber D, Casasanta N, Jain M, Fu W, et al. Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2024.12.020

BibTeX
@article{Patel2025,
  author = {Patel, Rima and Jin, Cao and Jaber, Diana and Casasanta, Nicole and Jain, Mayuri and Fu, Weijia and Wu, Catherine and Moshier, Erin and Tiersten, Amy},
  title = {Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2024.12.020}
}
Kostenlos starten →